Need professional-grade analysis? Visit stockanalysis.com
$80.47B
49.50
2,662
N/A
WuXi XDC Cayman Inc (2268) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at HKD60.35, down 6.58% from the previous close.
Over the past year, 2268 has traded between a low of HKD34.80 and a high of HKD85.10. The stock has gained 73.4% over this period. It is currently 29.1% below its 52-week high.
WuXi XDC Cayman Inc has a market capitalization of $80.47B, with a price-to-earnings ratio of 49.50.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Side-by-side comparison against top Healthcare peers.